NASDAQ$AVDL
Avadel Pharmaceuticals plc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Avadel Pharmaceuticals reported Q2 2025, revenue of $68.1M, net income of $9.7M, diluted EPS of $0.10.
For Q2 2025, Avadel Pharmaceuticals reported Revenue was $68.1M; net income was $9.7M; diluted EPS was $0.10. Management discusses operating trends, liquidity, capital priorities, and sector risks in the quarterly filing.
- Revenue $68.1M.
- Net income $9.7M.
- Diluted EPS $0.10.
- Avadel Pharmaceuticals MD&A highlights liquidity, capital, and core operating trends.
- Macro and competitive factors shape year-over-year comparisons.
Headline financials
Revenue & EPS history
Avadel · Revenue · Quarterly
$68.1M
Revenue by segment
Avadel · $7M total across 1 segment · Q3 2023
- LUMRYZ Net Product Revenue$7M—100.0%
Forward guidance
Avadel Pharmaceuticals discusses outlook, capital allocation, and key risks for upcoming periods in the filing.
Tailwinds
- Avadel Pharmaceuticals cites execution on strategic and operating priorities.
- Liquidity supports ongoing operations and investment.
- Management monitors demand and cost trends.
Headwinds
- Macro uncertainty may pressure volumes or margins.
- Competitive dynamics in core markets.
- One-time items can affect quarter-to-quarter comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports · overlaid with Q2 2025
-1.2%
Avg return
Earnings day
+1.2%
Avg return
5 days after
+2.3%
Avg return
30 days after
44%
28 / 64 earnings
Positive
+22.2%
Q4 2020
Best reaction
-26.3%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +0.4% | -1.0% | +12.9% | |
| Q2 2025 | +14.7% | +20.7% | +42.0% | |
| Q1 2025 | +9.1% | +10.5% | +12.1% | |
| Q4 2024 | -4.6% | +0.1% | -5.6% | |
| Q3 2024 | -26.3% | -33.1% | -34.9% | |
| Q2 2024 | -3.7% | +0.8% | -9.9% | |
| Q1 2024 | -12.9% | -7.8% | -16.9% | |
| Q4 2023 | +15.2% | +19.2% | +18.7% | |
| Q3 2023 | +6.9% | — | — | |
| Q2 2023 | -0.6% | — | — | |
| Q1 2023 | +5.4% | — | — | |
| Q4 2022 | +3.0% | — | — | |
| Q3 2022 | -0.3% | — | — | |
| Q2 2022 | +13.2% | — | — | |
| Q1 2022 | -5.0% | — | — | |
| Q4 2021 | +4.7% | — | — | |
| Q3 2021 | +7.3% | — | — | |
| Q2 2021 | -3.4% | — | — | |
| Q1 2021 | +1.1% | — | — | |
| Q4 2020 | +22.2% | — | — | |
| Q3 2020 | +11.7% | — | — | |
| Q2 2020 | -7.4% | — | — | |
| Q1 2020 | -2.5% | — | — | |
| Q4 2019 | -24.8% | — | — | |
| Q3 2019 | -2.7% | — | — | |
| Q2 2019 | -11.4% | — | — | |
| Q1 2019 | -3.3% | — | — | |
| Q4 2018 | -15.0% | — | — | |
| Q3 2018 | -25.6% | — | — | |
| Q2 2018 | -11.5% | — | — | |
| Q1 2018 | +4.0% | — | — | |
| Q4 2017 | -11.0% | — | — | |
| Q3 2017 | -1.3% | — | — | |
| Q2 2017 | -5.2% | — | — | |
| Q1 2017 | +1.6% | — | — | |
| Q4 2016 | +6.0% | — | — | |
| Q3 2016 | -2.8% | — | — | |
| Q3 2015 | -2.8% | — | — | |
| Q2 2016 | +1.0% | — | — | |
| Q1 2016 | +1.4% | — | — | |
| Q4 2015 | +1.6% | — | — | |
| Q2 2015 | -10.8% | — | — | |
| Q1 2015 | +6.0% | — | — | |
| Q4 2014 | -0.3% | — | — | |
| Q3 2014 | +0.2% | — | — | |
| Q2 2014 | +1.3% | — | — | |
| Q1 2013 | +3.4% | — | — | |
| Q1 2014 | +3.4% | — | — | |
| Q4 2013 | +2.3% | — | — | |
| Q3 2012 | -1.2% | — | — | |
| Q3 2013 | -1.2% | — | — | |
| Q2 2013 | -5.0% | — | — | |
| Q4 2012 | +1.4% | — | — | |
| Q2 2011 | +6.0% | — | — | |
| Q2 2012 | +6.0% | — | — | |
| Q1 2011 | -1.1% | — | — | |
| Q4 2011 | -4.8% | — | — | |
| Q4 2009 | -4.8% | — | — | |
| Q4 2010 | -4.8% | — | — | |
| Q1 2012 | -4.5% | — | — | |
| Q3 2011 | -5.0% | — | — | |
| Q3 2010 | -0.7% | — | — | |
| Q2 2010 | -6.9% | — | — | |
| Q1 2010 | -4.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro